Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- estradiol / norethindrone topical
- pirfenidone
Interactions between your drugs
estradiol topical pirfenidone
Applies to: estradiol / norethindrone topical, pirfenidone
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of pirfenidone, which is primarily (70% to 80%) metabolized by the isoenzyme. Other CYP450 isoenzymes also contribute to a minor extent, including CYP450 2C9, 2C19, 2D6, and 2E1. Concomitant inhibition of one or more of these isoenzymes in addition to CYP450 1A2 is expected to further increase the magnitude of interaction. In 27 healthy study subjects, administration of a single 801 mg dose of pirfenidone on day 6 of treatment with the moderate CYP450 1A2 inhibitor ciprofloxacin (750 mg twice daily) increased pirfenidone peak plasma concentration (Cmax) and systemic exposure (AUC) by 23% and 81%, respectively. In 25 healthy nonsmokers and 25 smokers who were administered a single dose of pirfenidone with the potent CYP450 1A2 inhibitor fluvoxamine (50 mg at bedtime for 3 days; 50 mg twice a day for 3 days; then 50 mg in the morning and 100 mg at bedtime for 4 days), pirfenidone AUC increased approximately 4-fold in nonsmoking subjects and 7-fold in smoking subjects. Fluvoxamine also inhibits CYP450 2C9, 2C19 and 2D6, although the extent to which these effects contribute to the interaction has not been established.
MANAGEMENT: Caution is advised when pirfenidone is used concomitantly with CYP450 1A2 inhibitors. Patients should be closely monitored for adverse reactions such as hepatotoxicity, photosensitivity, rash, nausea, diarrhea, vomiting and dyspepsia, and consideration be given to dosage reduction, brief interruption, or permanent discontinuation of pirfenidone if clinically necessary in accordance with the product labeling. Coadministration of pirfenidone with CYP450 1A2 inhibitors in addition to inhibitors of other CYP450 isoenzymes involved in the metabolism of pirfenidone should be avoided, including significant inhibitors of CYP450 2C9 (e.g., amiodarone, fluconazole, imatinib, gemfibrozil, miconazole), 2C19 (e.g., chloramphenicol, cimetidine, esomeprazole, fluconazole, lansoprazole, omeprazole), and/or 2D6 (e.g., bupropion, cinacalcet, fluoxetine, paroxetine, quinidine, terbinafine).
Drug and food interactions
pirfenidone food
Applies to: pirfenidone
Pirfenidone should be taken with food to help reduce dizziness and gastrointestinal side effects such as diarrhea, nausea, vomiting, and upset stomach. Avoid smoking during treatment, as cigarette smoking can reduce the blood levels and effects of pirfenidone. If you are a smoker, you should try to quit smoking before starting treatment. Talk to your doctor or pharmacist if you have any questions or concerns, or need help in finding a smoking cessation program. You should also avoid consuming grapefruit or grapefruit juice while taking pirfenidone, as it may increase blood levels of the medication and lead to more side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Activella
Activella is used for atrophic urethritis, atrophic vaginitis, hypoestrogenism, postmenopausal symptoms
Angeliq
Angeliq (drospirenone and estradiol) is used to treat the symptoms of menopause such as hot ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Bijuva
Bijuva (estradiol and progesterone) is used to reduce moderate to severe hot flashes in menopausal ...
Climara Pro
Climara Pro (estradiol and levonorgestrel) treats menopause symptoms and helps prevent ...
CombiPatch
CombiPatch is used for atrophic urethritis, atrophic vaginitis, hypoestrogenism, postmenopausal symptoms
Covaryx
Covaryx is used for hot flashes, menopausal disorders, postmenopausal symptoms
Covaryx HS
Covaryx HS is used for hot flashes, menopausal disorders, postmenopausal symptoms
Duavee
Duavee (bazedoxifene/conjugated estrogens) is used to treat hot flashes and prevent postmenopausal ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.